Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma - A Gynecologic Oncology Group Study

Frederick B. Stehman, John A. Blessing, Howard D. Homesley, John L. Currie, Edgardo L. Yordan

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

Original languageEnglish (US)
Pages (from-to)331-333
Number of pages3
JournalInvestigational New Drugs
Volume2
Issue number3
DOIs
StatePublished - Sep 1984

Keywords

  • cervix
  • dianhydrogalactitol
  • galactitol
  • non-squamous-chemotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma - A Gynecologic Oncology Group Study'. Together they form a unique fingerprint.

  • Cite this